Last reviewed · How we verify
E3810
E3810 is a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide signaling in the brain.
E3810 is a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide signaling in the brain. Used for Schizophrenia, Parkinson's disease psychosis.
At a glance
| Generic name | E3810 |
|---|---|
| Also known as | Aciphex |
| Sponsor | Eisai Co., Ltd. |
| Drug class | PDE10A inhibitor |
| Target | PDE10A (Phosphodiesterase 10A) |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | Phase 3 |
Mechanism of action
PDE10A is predominantly expressed in medium spiny neurons of the striatum and is involved in dopamine and glutamate signaling. By inhibiting PDE10A, E3810 enhances cAMP and cGMP signaling, which modulates neuronal activity and may restore balance in dysregulated neural circuits. This mechanism is hypothesized to be beneficial in neuropsychiatric and neurodegenerative conditions.
Approved indications
- Schizophrenia
- Parkinson's disease psychosis
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
Key clinical trials
- A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer (PHASE2)
- Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors (PHASE1, PHASE2)
- A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (PHASE1, PHASE2)
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy (PHASE1, PHASE2)
- A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients (PHASE3)
- A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor (PHASE1, PHASE2)
- A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer (PHASE2)
- This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |